Why Certification of Packaging Materials is Critical

Packaging materials are in direct contact with the drug product throughout its shelf life. They can influence the product’s quality, safety, and efficacy. Regulatory agencies require manufacturers to demonstrate that these materials are suitable for use, have been properly tested, and are sourced from approved suppliers. Certification ensures that the packaging components:

• ✓ Meet predefined specifications and pharmacopeial standards (USP, Ph.Eur, JP)
• ✓ Are free from extractables, leachables, or other harmful contaminants
• ✓ Have consistent physical and chemical performance
• ✓ Are backed by complete documentation and change control records

Essential Certificates and Regulatory Documentation

The following documents must be obtained and maintained for each packaging component used in stability studies:

• Certificate of Analysis (CoA): Supplier-issued report confirming batch-wise testing results
• Certificate of Compliance (CoC): Declaration that the product complies with GMP, pharmacopeia, and regulatory expectations
• USP , , , Reports: Documentation of extractables, leachables, and physical properties
• DMF References: Drug Master File references (Type III) for container closure systems filed with the FDA
• Change Notification Policy: Supplier’s commitment to inform about composition or process changes

Key Regulatory Guidelines and Standards

When selecting and certifying packaging materials, manufacturers must refer to key global guidelines, including:

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• ICH Q3C/Q3D: Impurities including residual solvents and elemental impurities
• 21 CFR Part 211 and 820: US GMP requirements for packaging
• EU GMP Annex 9: Use of primary and printed packaging materials
• WHO TRS Annexes on Stability and Packaging

Packaging Certification in Regulatory Dossiers

Packaging material certification data must be included in:

• CTD Module 3.2.P.7: Container closure system information
• Module 3.2.R: Regional-specific certifications and GMP declarations
• Risk Assessments: Related to packaging interactions and stability

Failure to provide complete documentation may result in deficiency letters, delayed approvals, or even rejections.

Case Example: EMA Query on Container Closure Declaration

During centralized review, the EMA requested additional data for a parenteral product. The sponsor had failed to submit extractables and leachables data for the rubber stopper. Despite having stability data, approval was delayed by 4 months until appropriate EMA expectations were met with certified reports and supporting risk assessments.

Supplier Qualification and Audit Expectations

Packaging suppliers play a pivotal role in ensuring regulatory compliance. Pharmaceutical companies must:

• ✔ Qualify suppliers through GMP audits and quality questionnaires
• ✔ Obtain CoA and CoC for each shipment or batch used
• ✔ Implement Quality Agreements covering responsibilities and notification clauses
• ✔ Periodically re-evaluate suppliers based on risk and performance

Auditors from regulatory agencies routinely inspect documentation related to supplier qualification, material traceability, and change management.

Testing and Verification of Certified Packaging Materials

Even when a CoA is provided, pharma companies must conduct their own verification testing to confirm compliance:

• Identification by FTIR or other spectroscopic techniques
• Physical inspection (dimensions, weight, torque, clarity)
• Extractables testing if new supplier or change in formulation
• Label and ink testing for migration or solvent compatibility
• Documentation of test results, review by QA

Checklist for Packaging Certification Compliance

• ☑ Have all packaging components undergone extractables and leachables testing?
• ☑ Is the packaging material certified for intended use (e.g., oral, parenteral)?
• ☑ Are all CoA and CoC records traceable and reviewed by QA?
• ☑ Has the supplier been GMP audited within the last 3 years?
• ☑ Are packaging specifications and certificates filed in the product dossier?

Cross-Linking Packaging and Stability Programs

Certifications must directly align with the packaging used in actual stability testing. Using non-certified or alternate packaging will compromise data integrity. As a best practice:

• Link packaging certificate ID with each stability batch record
• Include certificates in stability reports
• Flag packaging-related OOS or trends during stability trending reviews

More on packaging SOPs and documentation can be found at pharma SOPs.

Conclusion

Certifying packaging materials used in stability studies is a critical component of regulatory compliance. Through thorough supplier qualification, verification testing, documentation control, and inclusion in regulatory submissions, pharma manufacturers can safeguard product quality, avoid regulatory delays, and meet global standards. Certification isn’t just paperwork—it’s an assurance of integrity, consistency, and patient safety.

References:

• ICH Q1A(R2), Q3C, Q3D Guidelines
• USP Chapters <661.1>, <661.2>, <671>, <381>
• USFDA Guidance on Container Closure Systems
• EU GMP Annex 9: Packaging Materials
• WHO TRS 1010 Annex 10 – Stability Guidelines

💥 1. Incomplete Container-Closure Description

One of the most frequent reasons for regulatory queries is the lack of clarity around packaging components. Regulators expect a precise description of:

• ✅ Primary packaging (e.g., HDPE bottle, blister foil)
• ✅ Secondary packaging (e.g., carton, leaflet)
• ✅ Closure system (e.g., desiccant, induction seal, cap liner)

Always match your stability study batches with the final commercial packaging intended for use.

🔴 2. No Data on Packaging Compatibility

Both EMA and FDA require evidence that the packaging material does not react with or degrade the drug product. Provide:

• ✅ Extractables and leachables studies
• ✅ Adsorption/absorption studies
• ✅ Moisture vapor transmission rate (MVTR) for polymers

Refer to equipment qualification documentation for any test chambers or UV stability setups used.

📝 3. Ignoring Photostability Packaging Requirements

Under ICH Q1B, photostability testing is essential for drug products. If opaque packaging is used, justify the selection with:

• ✅ Light transmission studies
• ✅ Proof that packaging shields from UV/visible spectrum

Without this, submissions risk rejection during EMA’s Module 3 review.

⚠️ 4. Mismatch Between Label Claim and Packaging

If your label states 24-month shelf life at 25°C/60% RH, but the packaging data doesn’t support this, expect a regulatory comment. Always reconcile:

• ✅ Shelf-life claim with validated packaging data
• ✅ Zone-specific storage conditions (e.g., IVb vs. ICH Zone II)
• ✅ Stability results with packaging type and batch configuration

🤙 5. Missing Tamper-Evidence or Moisture Barrier Details

Both EMA and FDA are placing increasing emphasis on consumer safety. Failure to include:

• ✅ Details on tamper-evident packaging
• ✅ Moisture ingress data
• ✅ Accelerated aging for packaging shelf life

can result in delays. Include all related SOPs and specifications in the CTD submission.

⚡ 6. Lack of Regional Packaging Variants

Different regions have distinct climatic zones and regulatory expectations. Submitting the same packaging data for FDA and EMA may not be sufficient. To ensure compliance:

• ✅ For FDA: Data under Zone II (25°C/60% RH or 30°C/65% RH)
• ✅ For ASEAN or TGA: Submit Zone IVb (30°C/75% RH) data
• ✅ If packaging changes for a region, submit comparative stability profiles

This ensures your packaging is validated across regional expectations, not just globally harmonized protocols.

📦 7. Inadequate Change Control History

Regulators often request the change control history of packaging material. Common gaps include:

• ✅ Undocumented supplier changes
• ✅ Updates to packaging film or resin not reflected in SOPs
• ✅ Absence of requalification post-change

Ensure that any change in primary packaging is evaluated via a stability impact assessment and documented accordingly.

🔧 8. Unsupported Claims About Barrier Protection

Terms like “moisture-proof” or “light-resistant” must be backed by quantitative data. Always provide:

• ✅ MVTR or OTR values (for moisture/oxygen permeability)
• ✅ UV/visible light shielding data
• ✅ Accelerated degradation results under stress conditions

Submissions that lack empirical evidence for such claims often receive deficiency letters from EMA.

📔 9. Missing Packaging Validation Reports

Packaging validation is an essential GMP requirement. Your stability section should cross-reference:

• ✅ Line trial data
• ✅ Transportation studies
• ✅ Seal integrity and capping torque validation

Missing these details can result in approval delays, especially during FDA facility inspections.

❗ 10. Submitting Outdated Packaging Specifications

Ensure all documentation reflects current specifications, including:

• ✅ Material of construction (MOC)
• ✅ Supplier CoA and mechanical specs
• ✅ Stability commitments tied to packaging revisions

Outdated specs are a red flag during regulatory reviews and may trigger repeat queries.

🎯 Conclusion: Prevent Packaging Pitfalls Before Submission

Stability data is only as reliable as the packaging used. By proactively avoiding these 10 packaging pitfalls, you significantly improve your chances of first-cycle approval across FDA, EMA, ASEAN, and TGA regions. Make sure every component in your clinical trial protocol or CTD dossier aligns with regulatory best practices and scientific justification.